CA3168201A1 - Group a strep immunogenic compositions with polysaccharide-protein conjugates - Google Patents

Group a strep immunogenic compositions with polysaccharide-protein conjugates Download PDF

Info

Publication number
CA3168201A1
CA3168201A1 CA3168201A CA3168201A CA3168201A1 CA 3168201 A1 CA3168201 A1 CA 3168201A1 CA 3168201 A CA3168201 A CA 3168201A CA 3168201 A CA3168201 A CA 3168201A CA 3168201 A1 CA3168201 A1 CA 3168201A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
immunogenic composition
gas
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168201A
Other languages
English (en)
French (fr)
Inventor
Jeffery C. FAIRMAN
Neeraj Kapoor
Peter T. Davey
Angie A. Sedra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaxcyte Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3168201A1 publication Critical patent/CA3168201A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/2111—C5a peptidase (3.4.21.110)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3168201A 2020-02-18 2021-02-17 Group a strep immunogenic compositions with polysaccharide-protein conjugates Pending CA3168201A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062977886P 2020-02-18 2020-02-18
US62/977,886 2020-02-18
US202063013924P 2020-04-22 2020-04-22
US63/013,924 2020-04-22
US202063090069P 2020-10-09 2020-10-09
US63/090,069 2020-10-09
US202063123293P 2020-12-09 2020-12-09
US63/123,293 2020-12-09
PCT/US2021/018402 WO2021167996A1 (en) 2020-02-18 2021-02-17 Group a strep immunogenic compositions with polysaccharide-protein conjugates

Publications (1)

Publication Number Publication Date
CA3168201A1 true CA3168201A1 (en) 2021-08-26

Family

ID=74860575

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168201A Pending CA3168201A1 (en) 2020-02-18 2021-02-17 Group a strep immunogenic compositions with polysaccharide-protein conjugates

Country Status (13)

Country Link
US (1) US20230293658A1 (enExample)
EP (1) EP4106807A1 (enExample)
JP (1) JP2023514332A (enExample)
KR (1) KR20220143107A (enExample)
CN (1) CN115175697A (enExample)
AU (1) AU2021224585A1 (enExample)
BR (1) BR112022016268A2 (enExample)
CA (1) CA3168201A1 (enExample)
IL (1) IL295702A (enExample)
MX (1) MX2022010129A (enExample)
PH (1) PH12022552118A1 (enExample)
TW (1) TW202136285A (enExample)
WO (1) WO2021167996A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230052958A (ko) 2020-08-19 2023-04-20 박사이트, 인코포레이티드 운반-단백질 폴리삭카라이드 접합 방법
EP4294452A4 (en) * 2021-02-17 2025-09-24 Vaxcyte Inc METHODS FOR PURIFYING POLYSACCHARIDES AND CORRESPONDING POLYPEPTIDE CONJUGATES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
BRPI0821240B8 (pt) * 2007-12-21 2022-10-04 Novartis Ag formas mutantes de estreptolisina o
CN102264444B (zh) 2008-10-27 2015-08-05 诺华股份有限公司 纯化方法
US20140294930A1 (en) 2011-08-04 2014-10-02 The Regents Of The University Of California STREPTOCOCCAL GlcNAc-LACKING GLYCOPOLYPEPTIDES, CELL WALL CARBOHYDRATES, STREPTOCOCCUS VACCINES, AND METHODS FOR MAKING AND USING THEM
RU2662970C2 (ru) * 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.

Also Published As

Publication number Publication date
AU2021224585A1 (en) 2022-10-13
WO2021167996A1 (en) 2021-08-26
TW202136285A (zh) 2021-10-01
JP2023514332A (ja) 2023-04-05
BR112022016268A2 (pt) 2022-10-11
CN115175697A (zh) 2022-10-11
PH12022552118A1 (en) 2024-01-29
EP4106807A1 (en) 2022-12-28
KR20220143107A (ko) 2022-10-24
MX2022010129A (es) 2022-09-05
US20230293658A1 (en) 2023-09-21
IL295702A (en) 2022-10-01

Similar Documents

Publication Publication Date Title
US8529913B2 (en) Immunogenic compositions for Streptococcus pyogenes
US8778358B2 (en) Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae
RU2498994C2 (ru) Мутантные формы стрептолизина о
CN102481349B (zh) 抗革兰氏阳性细菌疫苗中的Cna_B结构域
WO2022178015A1 (en) Purification processes for polysaccharides and polypeptide conjugates thereof
CN103974718A (zh) 基于艰难梭菌毒素的疫苗
MX2012000734A (es) Inmunogenos destoxificados de escherichia coli.
US20230293658A1 (en) Group a strep immunogenic compositions with polysaccharide-protein conjugates
EP2252634A1 (en) Hybrid polypeptides comprising gbs-80 and spb1 proteins of streptococcus
US20150273042A1 (en) Pilus proteins and compositions
AU2011275507B2 (en) A recombinant vaccine against Clostridium perfringens infection and epsilon (epsilon) toxin intoxication
US20200030430A1 (en) Immunogenic compositions
CN121490069A (zh) 肺炎链球菌蛋白疫苗
AU2013203028A1 (en) Cna_B domain antigens in vaccines against gram positive bacteria

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250203

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260209

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260209